Name: Latest research reports of Lupin Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Lupin Ltd.
Rating: 1
Author: BOB Capital Markets Ltd.

Lupin Ltd.

NSE: LUPIN | BSE: 500257 | ISIN: INE326A01037 | Industry: Pharmaceuticals
| Mid-range Performer

2105.3000 2.50 (0.12%)

NSE Jan 02, 2026 15:31 PM

Volume: 252.9K

Lupin Ltd.

05 Aug 2023

2105.30

0.12%

Lupin (SELL): Improvements visible; runup behind downgrade

Sell: Lupin Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Q1 a beat with revenue/EBITDA running 8%/25% ahead of consensus; gross margin improves to 65.9% (64.4 ex-licensing income)

Lupin Ltd. is trading above all available SMAs